Global Thyroid Gland Disorder Treatment Market is expected to gain a positive CAGR in the forthcoming period. The thyroid gland situated just below the Adam’s apple in front of the neck, intakes iodine from the diet and releases thyroid hormone. The thyroid hormone thus affects a person’s physical energy, temperature, mood and weight.
Thyroid diseases normally fall into two broad categories of disorders, abnormal growth and abnormal function in the gland. Such problems are common in general masses, particularly the geriatric population and women. Hence, most thyroid problems can be detected and treated in the first instance. Abnormality arises when functional disorders pertain to the gland producing little thyroid hormone or too much thyroid hormone.
Further, benign nodules do not commonly affect the patient’s health and these nodules occur in cases of abnormal cell growth. These nodules can put a pressure on the neck and end up the patient in some serious troubles such as swallowing, breathing and speaking if the size of benign appears to be too large. A thyroid gets triggered in the presence of such nodules.
Driving factors responsible for the growth of thyroid gland disorder treatment market includes rise in patients with iodine deficiency. Additionally, with invention of new drug technologies, the companies are now focusing on enhanced drug formulation using novel drug delivery technologies. Based on segmentation by disease type, the thyroid gland disorder treatment market includes hypothyroidism and hyperthyroidism. Based on segmentation by drug type, the thyroid gland disorder treatment industry includes levothyroxine, propacil, liothyronine, and imidazole.
Geographically, thyroid gland disorder treatment market spans North America, Latin America, Europe, Asia-Pacific, Middle-East and Africa. North America and Europe market is expected to gain a positive traction in the forthcoming period owing to increase in R&D techniques and better medical infrastructure. APAC and MEA market is anticipated to grow at a higher CAGR owing to higher prevalence of thyroid. Other factors such as low medical infrastructure and less favorable medical diagnoses in emerging countries is likely to contribute to the market growth. The key players in the thyroid gland disorder treatment market include AbbVie, Pfizer Inc, Merck & Co Inc, Allergan plc, Mylan N.V. GlaxoSmithKline Plc, Novartis AG, RLX LABS Inc, Sanofi S.A, and Abott Laboratories.
Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Thyroid Gland Disorders Treatment in these regions, from 2012 to 2022 (forecast), covering
• North America
• Southeast Asia
Global Thyroid Gland Disorders Treatment market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer; the top players including
• Pfizer, Inc
• Novartis International AG
• Abbott Laboratories
• AbbVie, Inc
• Takeda Pharmaceutical
• Allergan Plc
• Merck KGaA
• Lannett Company, Inc
• Mylan N.V
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including
Research Support Specialist, USA